Curious about the scientific content at the upcoming 17^th edition of EMUC (EMUC25)? The Steering Committee Members offer you a preview of some of the congress highlights in this article.

Not only for urologists

The EMUC scientific programme is also consistently relevant, timely, and beneficial to a broad range of specialists.

“Although urologists traditionally attend EMUC, the faculty and participants comprise medical oncologists, radiation oncologists, nuclear medicine radiologists, pathologists, and other experts who are involved in the care of GU cancer patients. This results in fruitful discussions and, of course, well-rounded solutions,” said Dr. Elena Castro (ES), a Steering Committee Member representing the European Society for Medical Oncology (ESMO).

She added, “Multidisciplinarity is what scientific societies believe should guide the care of patients with GU tumours.”

Content for every GU cancer care specialist

Prof. Arnulf Stenzl (DE), Secretary General of the European Association of Urology (EAU), highlighted the sessions that cover the role of artificial intelligence in supporting patients’ journeys. He said, “The discussions about imaging helping to avoid biopsy in urological cancers will be interesting for clinicians. The session on hereditary GU cancers will also be a key highlight for those who seek answers in this complex thematics.”

Dr. Alison Tree (GB) of the European SocieTy for Radiotherapy and Oncology (ESTRO) also shared more topics to look forward to at EMUC25.

“A topic that will be interesting to explore is how to make the future of GU oncology care sustainable while treating patients more effectively and efficiently. Participants can also enjoy learning from multi-disciplinary viewpoints during the case discussions on rare and unconventional pathologies, to learn more about the “Cinderella tumours”.

“In addition, the Game-Changing Session on the CREST, AMPLITUDE metastatic HSPCa, and PACE trials is a must-attend,” stated Dr. Tree.

Explore the EMUC25 scientific programme now to know more.

Have your say

Prof. Stenzl emphasised “EMUC25’s scientific content is always an amalgamation of the latest literature and developments in the field of uro-oncology, discussed with the delegates by the various players in the field of uro-oncology. “

Dr. Castro added, “Key opinion leaders, seasoned experts, and younger colleagues may have different perspectives and at EMUC, we listen to these voices. EMUC is also an excellent stage to present research in an international and interdisciplinary setting.

“Furthermore, several sessions and courses that take place in smaller groups are designed to offer participants opportunities to have their say. There is ample time for discussions, interaction, and networking, such as during the Poster Session, which is one of my favourite sessions,” concluded Dr. Castro.

Discover more about EMUC25 here. Interested in presenting at the congress? Check out the information on abstract submission.

If you would like to attend EMUC25 as a delegate, register now to take advantage of special rates.

The post United voices for prime GU cancer care: Specialists to convene at EMUC25 appeared first on EMUC25.

During “Treatment response criteria in mHSPC”, Dr. Wolfgang Fendler (DE), concluded that “Radiographic outcomes are number one for clinical trials on metastatic hormone-sensitive prostate cancer (mHSPC). Most of the radiographic response is often in line with or similar to the Prostate Cancer Working Group 3 (PCWG3) criteria.” He added that standardised reporting – prostate cancer molecular imaging standardised evaluation (PROMISE) – and PSMA-PET response criteria such as PSMA PET progression (PPP) and Response Evaluation Criteria in PSMA-imaging (RECIP) have been defined and are currently reviewed and renewed by the PCWG4.

Novel biomarkers

According to medical oncologist Dr. Gerhardt Attard (GB), the combination of androgen deprivation therapy (ADT), androgen receptor pathway inhibitor (ARPI) , and ARPI + radiotherapy (RT) (for low volume) should be the treatment backbone for mHSPC. “We want to intensify further treatments to that backbone. Molecular transcriptome expression-based tests could play a role in patient management but more data sets are required for practice change.”

In his presentation “Implementation of novel biomarkers for metastatic prostate cancer starting androgen deprivation therapy”, he also stated that clinical implications of some biological processes appear to differ by the metastatic state in terms of tumour load at presentation, underlying biology, and various treatment paradigms.

SBRT matters

In “Stereotactic body radiation therapy for oligoprogression in prostate cancer”, Dr. Tree stated that there is good evidence that RT for oligoprogressive prostate cancer improves PSA control. As seen in the ARTO trial, RT delays the time until the next treatment. More work is needed to determine if RT improves overall survival. She added that the optimal time to consolidate with RT is unknown or if it should be performed at different hormone-sensitive settings in the metastatic arena.

View the presentations in detail in the EMUC24 Resource Centre.

The post mHSPC and CRPC session covers treatment response criteria, novel biomarkers and SBRT appeared first on EMUC25.